How should I evaluate a hypercoagulable (thrombophilic) state?

Evaluation for Hypercoagulable State

Routine screening for hypercoagulable states is not recommended for most patients, but selective testing should be pursued in specific clinical scenarios where results will meaningfully alter management, particularly in young patients with unprovoked thrombosis, recurrent events, or thrombosis at unusual sites. 1, 2

When to Test: Clinical Scenarios That Warrant Evaluation

High-Yield Testing Scenarios

• Young patients under 50 years with ischemic stroke or TIA after complete standard workup (brain imaging, vascular imaging, cardiac evaluation including prolonged monitoring for at least 2 weeks) remains unrevealing 1

• Cryptogenic stroke with no identifiable cardioembolic, large vessel, or small vessel etiology after thorough evaluation 1

• Personal history of unprovoked venous thromboembolism (DVT or PE without clear precipitating factors like surgery, trauma, or prolonged immobilization) 1, 2

• Recurrent thrombotic events despite adequate anticoagulation or after discontinuation of therapy 1, 2

• Thrombosis at unusual sites including cerebral venous sinus thrombosis, mesenteric vein thrombosis, or portal vein thrombosis 3, 2

• Suspected paradoxical embolism (stroke with concurrent DVT and patent foramen ovale) 1

• First-degree relatives with idiopathic thrombosis before age 50, suggesting familial thrombophilia 1

Important Caveat

Universal screening is not cost-effective. Selective screening based on prior venous thromboembolism history is more cost-effective than universal screening, and most case-control studies have not found an association between hereditary hypercoagulable states and stroke in general patient populations. 3

What Tests to Order: A Tiered Approach

First-Line Laboratory Panel

• Complete blood count with platelet count to assess for thrombocytosis or other hematologic abnormalities 2

• Coagulation profile: PT/INR, aPTT, fibrinogen level, and D-dimer 2

• Antiphospholipid antibody panel (most clinically actionable):

  • Lupus anticoagulant
  • Anticardiolipin antibodies (IgG and IgM)
  • Anti-β2 glycoprotein I antibodies 1, 2

Second-Line Genetic and Protein Testing

• Factor V Leiden mutation (activated protein C resistance) - strongest association with venous thrombosis, 4.3-fold increased incidence in children with stroke, 2.0-fold increased risk in adults ≤50 years 3, 1

• Prothrombin G20210A mutation - associated with increased stroke risk in young adults 3, 1

• Natural anticoagulant deficiencies:

  • Protein C deficiency
  • Protein S deficiency
  • Antithrombin III deficiency 1, 2

• Homocysteine levels (fasting) for hyperhomocysteinemia 2

Critical Timing Considerations to Avoid False Results

Timing of testing is absolutely critical because acute thrombosis, inflammation, pregnancy, and anticoagulant therapy dramatically affect results. 2

Specific Timing Requirements

• Protein C, Protein S, and Antithrombin III: Defer testing for at least 4-6 weeks after acute stroke or thrombotic event, as these proteins are consumed during acute thrombosis and will be falsely low 1, 2

• Antiphospholipid antibodies: Require confirmation with repeat testing at least 6-12 weeks apart to meet diagnostic criteria for antiphospholipid syndrome 1, 2

• Factor VIII levels: Should be repeated up to 6 months later if initially elevated, as acute phase elevation can occur 1

• Patients on anticoagulation: Certain tests may need to be delayed until therapy is completed or require specialized interpretation 2

Sample Handling Requirements

• Obtain blood atraumatically, avoid testing during acute illness or pregnancy, and minimize patient stress 4

• Transport samples at room temperature, separate plasma promptly, and if processing is delayed >2 hours, freeze plasma at ≤-40°C 4

• Recognize that von Willebrand factor is an acute-phase reactant and may be falsely elevated during stress or illness 4

Management Based on Test Results

For Identified Inherited Thrombophilias

• Antiplatelet therapy is reasonable as first-line treatment for secondary stroke prevention in patients with identified inherited thrombophilias 1

• Warfarin with target INR 2.0-3.0 is an alternative option for patients with identified inherited thrombophilias 1

• If concurrent venous thrombosis is identified, anticoagulation is mandated regardless of stroke mechanism 1

• Long-term anticoagulation is probably indicated for patients with recurrent thrombotic events or cerebral venous thrombosis 1

For Antiphospholipid Syndrome

• Warfarin with target INR 2.0-3.0 is a reasonable treatment option when antiphospholipid syndrome is confirmed 1

• Low-dose aspirin (81 mg/d) is NOT indicated for primary stroke prevention in individuals who are persistently antiphospholipid antibody positive (Class III recommendation) 3

What NOT to Do: Common Pitfalls

• Do not perform genetic screening for primary stroke prevention in asymptomatic individuals - the usefulness is not well established (Class IIb recommendation) 3

• Do not rely solely on PT/aPTT to exclude hypercoagulability, as these tests miss many thrombophilias including von Willebrand disease and mild platelet function disorders 2, 4

• Do not test during acute thrombosis for protein C, protein S, or antithrombin III, as results will be falsely low and misleading 1, 2

• Do not order testing reflexively without considering how results will change management - most venous thromboembolic events occur during high-risk periods (surgery, trauma, pregnancy) regardless of underlying thrombophilia 3

• Do not overlook ABO blood type - individuals with blood type O have lower baseline von Willebrand factor levels, affecting result interpretation 4

Special Populations

Young Women with Stroke

Young women with ischemic stroke have a higher prevalence of antiphospholipid antibodies compared to other patient populations, making antiphospholipid testing particularly high-yield in this group. 3

Patients with Patent Foramen Ovale

The relationship between patent foramen ovale and thrombophilia deserves particular attention because it may affect both primary and secondary stroke prevention strategies, as thrombophilia increases risk of paradoxical embolism. 3

High-Risk Situations Requiring Prophylaxis

Most venous thromboembolic events in patients with thrombophilia occur during high-risk periods including surgery, trauma, or pregnancy, suggesting that antithrombotic prophylaxis during these periods is critical regardless of baseline thrombophilia status. 3